What is SDGR's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SDGR.

Stock Ratings / Health Care / SDGR / options

MRVI (37) ZYME (50) SEPN (63) SRPT (27) ⌘ Pro Terminal →

Schrodinger Inc. (SDGR) Options Positioning, Max Pain & Unusual Sweeps

$26.19 -3.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.98

Schrodinger Inc. (SDGR) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.03B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SDGR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Schrodinger Inc. (NASDAQ: SDGR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $26.19 (-3.50% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, SDGR ranks #230 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SDGR compare to MRVI and ZYME in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDGR carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SDGR leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SDGR?

▼

Per SDGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001490978), Schrodinger Inc. generated $255.9M in revenue (+23.3% YoY), -$103.3M in net income, and $12.5M in free cash flow against $726.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $25.98 (-0.82%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SDGR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY SDGR SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (23% of score)

Altman Z-Score 2.64 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$25.89-9.6% Next Q

Q2 (-2Q)

Grade D$23.40+14.2% Next Q

Q3 (-1Q)

Grade C-$26.72-2% Next Q

Current

Grade D+$26.19-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SDGR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SDGR currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.33) and Max Pain ($27.50) forces dealer call-delta covering toward $35.47.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SDGR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SDGR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SDGR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SDGR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SDGR)

✓Walkthrough of SDGR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SDGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +103.02%▲ ASCENDING CHANNEL

2026-11-03O $29.99H $29.99L $26.19C $26.19VOL 1.95M

RES: $37.70SUP: $19.12SMA50: $25.33SMA200: $16.87

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SDGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SDGR Butterfly Map → + Track SDGR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +23.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SDGR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SDGR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SDGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SDGR)

Health Care Rank #230 of 1015 ⚔️ MRVI vs SDGR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SDGR vs. MRVI, ZYME, SEPN, SRPT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Schrodinger Inc. (SDGR) ranks #230 by composite RQD confidence (53/100, grade D+) and #251 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, SDGR leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with SDGR at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SDGR ACTIVE Schrodinger Inc.	D+	53/100	—	55.7%	-35.0%	-3.50%	$2.03B	Benchmark Subject
MRVI Maravai LifeSciences Holdings Inc. (Class A)	D-	37/100	—	18.3%	-35.0%	-7.94%	$2.03B	/mrvi-vs-sdgr →
ZYME Zymeworks Inc.	D	50/100	—	—	-32.2%	+1.33%	$2.02B	/zyme-vs-sdgr →
SEPN Septerna Inc.	C	63/100	—	—	-20.7%	-1.82%	$2.05B	/sepn-vs-sdgr →
SRPT Sarepta Therapeutics Inc.	E	27/100	—	96.0%	-35.0%	-1.61%	$1.97B	/srpt-vs-sdgr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001490978 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Schrodinger Inc. (SDGR) reported GAAP revenue of $255.9M (+23.3% vs. FY2024 revenue of $207.5M , and +18.1% cumulative change since FY2023) , GAAP net income of -$103.3M, operating cash flow of $13.9M, and free cash flow of $12.5M (+107.6% YoY). On the balance sheet, SDGR closed FY2025 with $726.2M in total assets against $0 in total debt (Altman Z-Score: 2.64, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$255.9M	-$103.3M	$13.9M	$12.5M	$726.2M	—
FY2024 (FY)	2024-12-31	$207.5M	-$187.1M	-$157.4M	-$164.7M	$823.2M	—
FY2023 (FY)	2023-12-31	$216.7M	$40.7M	-$136.7M	-$136.7M	—	—

3. SDGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SDGR compare to MRVI and ZYME in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SDGR?

Where is SDGR trading relative to its 50-day, 200-day, and 52-week technical levels?

SDGR last traded at $26.19 (-3.50% on volume of 1,392,057 shares), positioning the stock +3.40% above its 50-day simple moving average ($25.33) and +55.25% above its 200-day simple moving average ($16.87). Across its 52-week range of $10.94 to $33.78, SDGR sits at the 66.8% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($22.92 to $29.46).

Direct Sub-Reports: SDGR RQD Cockpit SDGR 12M Forecast SDGR Earnings & Move SDGR Dividends & DRIP SDGR Insiders & 13F SDGR Whale Options SDGR Profit Sankey SDGR News & Why

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

SDGR — Schrodinger Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Schrodinger Inc. (SDGR) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $26.19 (-3.50% 1D, market capitalization $2.03B).

Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 55.7%, operating margin of -60.0%, and free cash flow yield of 0.56%.
Whale 13F & Options Flow (14/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.64, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Schrodinger Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $2.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Schrodinger Inc. (SDGR) reported $255.9M in annual revenue (up from $207.5M in FY2024, +23.3% YoY) and -$103.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($216.7M revenue, $40.7M net income) through FY2025, SDGR scaled operating cash flow to $13.9M and free cash flow to $12.5M, backed by $726.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.56% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $10.94 – $33.78 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided source data. — for detailed ripple analysis beyond sector classification (Health Care, Biotechnology: Pharmaceutical Preparations).

Key Question #1: Can SDGR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $255.9M and free cash flow of $12.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SDGR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SDGR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Schrodinger Inc. (SDGR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SDGR Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 22h ago

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Yahoo Finance report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Schrodinger Stock Price Forecast. Should You Buy SDGR?

StockInvest.us report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Schrodinger Inc (SDGR) Stock Down 11.3% but Still Overvalued -- GF Score: 71/100

GuruFocus report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth

Yahoo Finance report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Up to 40% of lithium ions in battery fluid cluster. This could help guide battery design.

Stock Titan report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

Is Schrödinger (SDGR) Fully Valued As Analyst Upgrades Back Its AI Drug Discovery Story?

Simply Wall St report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Schrodinger Inc. (SDGR) Affects Rotational Strategy Timing

Stock Traders Daily report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GuruFocus • 1d ago

Schrodinger Inc (SDGR) Shares Fall 5.0% -- What GF Score of 72 T

GuruFocus report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SDGR Bull vs. Bear Conversation Board — What's Your Call at $26.19?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SDGR 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $34.20 (+26.0%)

📌 Pinned Debate

Institutional whale-flow score of 17/20 and a forensic balance sheet with Piotroski F 7/9 and Altman Z 2.64 signal underlying accumulat

Long SDGR at $27.14 targeting $34.20. Institutional whale-flow score of 17/20 and a forensic balance sheet with Piotroski F 7/9 and Altman Z 2.64 signal underlying accumulation and financial stability.. Institutional whale score is 14/20 and the risk/reward vs. the $10.94 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@QuantViper Agree on the RQD 53/100 quality, though with 1.0 beta I'm scaling in with half-size at $27.14 and keeping dry powder in case we test $25.24.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $22.80 (-16.0%)

Spot @ $27.14

ROIC of -35%, operating margin of -60%, and a 0.56% FCF yield show the business is not currently generating returns on its capital.

Here is the bear case nobody on the bull side wants to address on SDGR: ROIC of -35%, operating margin of -60%, and a 0.56% FCF yield show the business is not currently generating returns on its capital.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.